All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-PSCA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human PSCA. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-PSCA antibody linked to CD3-zeta signaling domain, as well as a inducible construct compressing MyD88, CD40, and FKBP. The iMC-based CAR-T cells show improved tumor killing and expansion in a rimiducid-dependent manner. And the vector product was designed for the treatment of non-Hodgkin lymphoma.
CAR Construction : Fig.1 After treatment with PBS or 1G8 (20 Ag/mL) for 24 hours, cells were stained with Annexin V and PI and analyzed by FACS. 1G8 induces cell death. Gu, Z., Yamashiro, J., Kono, E., & Reiter, R. E. (2005). Anti–prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer research, 65(20), 9495-9500. |
CAR Construction : 1G8 scFv-28ζ Fig.2 Generation of anti-prostate stem cell antigen (PSCA) CAR-T cells. Representative flow cytometric analyses of transfected T cells detected by flow cytometry. Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11. |
CAR Construction : 1G8 scFv-28ζ Fig.3 Anti-PSCA CAR-T cells exhibited dramatic antitumor efficacy ex vivo. The lytic capacity towards MKN-28 cells, was analyzed at the indicated effector-to-target ratios in a 24 h lysis assay. Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11. |
CAR Construction : 1G8 scFv-28ζ Fig.4 Anti-PSCA CAR-T cells efficiently reduced tumor progression in BGC-823 models. Percentage of T cells in the spleen of the BGC-823 models and representative FACS plots of the i.v group and the p.t group, respectively. Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11. |
CAR Construction : 1G8 scFv-28ζ Fig.5 Anti-PSCA CAR-T cells suppressed tumor progression in MKN-28 model. Schematic representation depicting the time course of the experiment. Wu, D., Lv, J., Zhao, R., Wu, Z., Zheng, D., Shi, J., ... & Yao, Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8(1), 1-11. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PSCA (1G8) h(CD28-CD3ζ, MyD88) Conditional CAR, pCDCAR1 (CAR-LC275). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION